Kiora Pharmaceuticals Book Value Per Share Growth & History (KPRX)
Kiora Pharmaceuticals's book value per share was $4.29 for fiscal 2025.
View full Kiora Pharmaceuticals company overviewKiora Pharmaceuticals annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.29 | -$4.30 | −50.06% |
| 2024 | 2024-12-31 | $8.58 | $1.45 | +20.30% |
| 2023 | 2023-12-31 | $7.14 | -$507.73 | −98.61% |
| 2022 | 2022-12-31 | $514.87 | -$3,218.84 | −86.21% |
| 2021 | 2021-12-31 | $3,733.70 | -$1,945.49 | −34.26% |
| 2020 | 2020-12-31 | $5,679.19 | $412.05 | +7.82% |
| 2019 | 2019-12-31 | $5,267.14 | -$4,270.95 | −44.78% |
| 2018 | 2018-12-31 | $9,538.10 | $100,072.52 | — |
| 2017 | 2017-12-31 | -$90,534.42 | -$64,169.66 | — |
| 2016 | 2016-12-31 | -$26,364.77 | -$670,877.71 | — |
| 2015 | 2015-12-31 | $644,512.95 | $197,413,880.47 | — |
| 2014 | 2014-12-31 | -$196,769,367.52 | — | — |
Kiora Pharmaceuticals quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.81 | -$2.64 | −40.92% |
| Q1 2026 | 2026-03-31 | $3.49 | -$4.41 | −55.82% |
| Q4 2025 | 2025-12-31 | $4.29 | -$4.30 | −50.06% |
| Q3 2025 | 2025-09-30 | $6.53 | -$3.48 | −34.78% |
| Q2 2025 | 2025-06-30 | $6.44 | -$4.70 | −42.17% |
| Q1 2025 | 2025-03-31 | $7.90 | -$99.89 | −92.67% |
| Q4 2024 | 2024-12-31 | $8.58 | $1.45 | +20.30% |
| Q3 2024 | 2024-09-30 | $10.01 | -$75.45 | −88.29% |
| Q2 2024 | 2024-06-30 | $11.14 | -$148.92 | −93.04% |
| Q1 2024 | 2024-03-31 | $107.79 | -$321.24 | −74.88% |
| Q4 2023 | 2023-12-31 | $7.14 | -$507.73 | −98.61% |
| Q3 2023 | 2023-09-30 | $85.45 | -$705.14 | −89.19% |
| Q2 2023 | 2023-06-30 | $160.06 | -$2,014.60 | −92.64% |
| Q1 2023 | 2023-03-31 | $429.03 | -$2,454.10 | −85.12% |
| Q4 2022 | 2022-12-31 | $514.87 | -$3,218.84 | −86.21% |
| Q3 2022 | 2022-09-30 | $790.60 | -$4,479.79 | −85.00% |
| Q2 2022 | 2022-06-30 | $2,174.66 | -$4,076.33 | −65.21% |
| Q1 2022 | 2022-03-31 | $2,883.13 | -$4,421.06 | −60.53% |
| Q4 2021 | 2021-12-31 | $3,733.70 | -$1,945.49 | −34.26% |
| Q3 2021 | 2021-09-30 | $5,270.39 | $1,091.65 | +26.12% |
| Q2 2021 | 2021-06-30 | $6,251.00 | $785.09 | +14.36% |
| Q1 2021 | 2021-03-31 | $7,304.19 | $772.74 | +11.83% |
| Q4 2020 | 2020-12-31 | $5,679.19 | $412.05 | +7.82% |
| Q3 2020 | 2020-09-30 | $4,178.74 | -$1,387.79 | −24.93% |
| Q2 2020 | 2020-06-30 | $5,465.91 | -$144,919.53 | −96.37% |
| Q1 2020 | 2020-03-31 | $6,531.44 | -$172,074.49 | −96.34% |
| Q4 2019 | 2019-12-31 | $5,267.14 | -$4,270.95 | −44.78% |
| Q3 2019 | 2019-09-30 | $5,566.53 | -$201,597.10 | −97.31% |
| Q2 2019 | 2019-06-30 | $150,385.44 | -$108,804.47 | −41.98% |
| Q1 2019 | 2019-03-31 | $178,605.93 | -$69,375.19 | −27.98% |
| Q4 2018 | 2018-12-31 | $9,538.10 | $100,072.52 | — |
| Q3 2018 | 2018-09-30 | $207,163.63 | $175,143.63 | +546.98% |
| Q2 2018 | 2018-06-30 | $259,189.91 | $43,865.21 | +20.37% |
| Q1 2018 | 2018-03-31 | $247,981.12 | $333,424.39 | — |
| Q4 2017 | 2017-12-31 | -$90,534.42 | -$64,169.66 | — |
| Q3 2017 | 2017-09-30 | $32,020.00 | -$242,485.20 | −88.34% |
| Q2 2017 | 2017-06-30 | $215,324.70 | -$370,535.83 | −63.25% |
| Q1 2017 | 2017-03-31 | -$85,443.26 | -$733,095.94 | — |
| Q4 2016 | 2016-12-31 | -$26,364.77 | -$670,877.71 | — |
| Q3 2016 | 2016-09-30 | $274,505.21 | -$644,618.41 | −70.13% |
| Q2 2016 | 2016-06-30 | $585,860.54 | $471,481.16 | +412.21% |
| Q1 2016 | 2016-03-31 | $647,652.67 | $375,201.01 | +137.71% |
| Q4 2015 | 2015-12-31 | $644,512.95 | $5,191,538.99 | — |
| Q3 2015 | 2015-09-30 | $919,123.61 | — | — |
| Q2 2015 | 2015-06-30 | $114,379.38 | — | — |
| Q1 2015 | 2015-03-31 | $272,451.66 | — | — |
| Q4 2014 | 2014-12-31 | -$4,547,026.04 | — | — |
Kiora Pharmaceuticals book value per share trends
Over the last five fiscal years, Kiora Pharmaceuticals's book value per share decreased from $5,679.19 to $4.29, a change of -$5,674.90. The latest reported quarter, Q2 2026, shows $3.81.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kiora Pharmaceuticals source filings ↗